1 Blood rheology in vitro and in vivo

Lowe, G. D. O.

doi:10.1016/s0950-3536(87)80018-5

Cited by 108 publications

(58 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Damage index scores were not performed in the current study. Elevation in WBV among SLE patients with arterial events was most prominent at low shear rates, an environment in which erythrocyte aggregation and rouleaux formation are thought to be major determinants of WBV (16,20). Ernst et al (28) documented increased erythrocyte aggregates and normal erythrocyte deformability in patients with SLE relative to controls, which is consonant with our findings of elevated WBV at low shear rates in patients with SLE.…”

Section: Discussionsupporting

confidence: 90%

“…At high shear rates, normal erythrocytes deform and cell-cell aggregates are broken apart. Excessive rigidity of erythrocytes, such as seen in hypertension and diabetes (17)(18)(19), results in increased WBV at high shear rates, due to the failure of erythrocytes to deform in high velocity conditions (16,20). In contrast, at low shear rates, excessive erythrocyte rigidity may lower WBV due to impairment in the formation of erythrocyte aggregates.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Whole blood viscosity and arterial thrombotic events in patients with systemic lupus erythematosus

Booth¹,

Chohan²,

Curran³

et al. 2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. To determine if whole blood viscosity (WBV), a rheologic variable contributing to risk of myocardial infarction and stroke in the general population, is elevated in patients with systemic lupus erythematosus (SLE), particularly SLE patients with a history of thrombotic or atherothrombotic events. Because the high rates of arterial and venous thrombosis in lupus cannot be explained by traditional risk factors, elevated WBV may be an easily measurable nontraditional risk factor to identify SLE patients at high risk for thrombotic events. Methods. Sixty SLE patients (30 with a history of a thrombotic event) and 20 matched controls were recruited into the study. The thrombosis group was further subdivided into an arterial thrombosis group (n ‫؍‬ 17). WBV values were determined at 9 different shear rates (1, 2, 5, 10, 50, 100, 150, 300, and 1,000 seconds ؊1 ). WBV was then compared between groups by repeated-measures analysis of variance. Results. SLE patients with a history of arterial events had significantly elevated WBV relative to either controls (P ‫؍‬ 0.022) or SLE patients without arterial events (P ‫؍‬ 0.014). WBV in the total SLE group did not differ from controls. Differences in WBV were most prominent at lower shear rates (1, 2, 5, 10, 50, and 100 seconds ؊1 ). Anticoagulation, prednisone dose, and antiphospholipid antibodies did not significantly impact WBV. Conclusion. Our study demonstrated that WBV is selectively elevated in patients with SLE with a history of arterial events. Although this association is striking, longitudinal studies are needed to assess the positive predictive value of WBV for atherothrombotic events in SLE.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Whole blood viscosity and arterial thrombotic events in patients with systemic lupus erythematosus

Booth¹,

Chohan²,

Curran³

et al. 2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…However, in patients with peripheral consumption of fibrinogen, the production rates of fibrinogen can reach up to 20-fold increase from baseline rates . Its elevation in acute phase response might affect plasma viscosity and the erythrocyte sedimentation rate (ESR) (Lowe, 1987). Fibrinogen, plasma viscosity and ESR have been shown to be independent predictors of coronary heart disease events (Danesh et al, 1998;Lowe & Rumley, 1999;Danesh et al, 2000).…”

Section: Fibrinogenmentioning

confidence: 99%

Cryoprecipitate transfusion: assessing appropriateness and dosing in trauma

Nascimento¹,

Rizoli²,

Rubenfeld³

et al. 2011

Transfusion Medicine

View full text Add to dashboard Cite

Cryoprecipitate is commonly used outside guidelines. In trauma, the appropriate cryoprecipitate dose and its impact on plasma fibrinogen levels are unclear.This retrospective study aims to evaluate: (1) the appropriateness of cryoprecipitate transfusion in trauma; and (2) the plasma fibrinogen response to cryoprecipitate transfusion during massive transfusion in trauma.Fibrinogen levels of < 1.0 g/L within 2 and 6 hours of cryoprecipitate transfusion were used for assessing appropriateness. Out of 394 events, 238 (60%) and 259 (66%) were considered appropriate using 2 and 6 hour criteria, respectively. A dose of 8.7 (±1.7) units caused a mean increase in fibrinogen levels of 0.55 (±0.24) g/L, or 0.06g/L per unit.In our hospital, where transfusion guidelines and policies for rapid blood product and laboratory turnaround times exist, it is possible to achieve high rates of appropriateness for cryoprecipitate transfusion in trauma. The current recommended dose causes a modest increase in fibrinogen levels.iii

show abstract

“…It is possible that this finding is a consequence of the relatively small number of patients in the study (ie, a type I statistical error). However, the observation that plasma viscosity increased in 12 of the 14 patients treated with losartan, with this increase being of physiological significance in six patients (ie, Ͼ0.06 mPa sec), 29 indicates that confirmatory data are required from a larger study. The possible reasons for the different effects of losartan and enalapril on plasma viscosity is not apparent from the data of the present study.…”

Section: Discussionmentioning

confidence: 98%

Haemorheological effects of losartan and enalapril in patients with renal parenchymal disease and hypertension

Shand

2000

J Hum Hypertens

View full text Add to dashboard Cite

The objective of this study was to compare the effects of the angiotensin II (ang II) antagonist, losartan and the angiotensin-converting enzyme inhibitor (ACEI), enalapril on haemorheology. Twenty-nine patients with renal parenchymal disease and hypertension were enrolled in the prospective, open, parallel study that involved a 14-day washout period followed by a 120-day treatment period. Patients were allocated randomly to receive either losartan 50-100 mg/day (n ‫؍‬ 15) or enalapril 2.5-10 mg/day (n ‫؍‬ 14) to achieve blood pressure control Ͻ140/90 mm Hg. Blood pressure, haemorheology profile and plasma fibrinogen concentration were measured after the washout phase and after 2, 10, 60, and 120 days of treatment. The data were analysed using ANOVA with repeated measures. Twenty-seven patients completed the study. Treatment with both losartan and enalapril was associated with a significant decrease (P Ͻ 0.05) in relative high shear rate whole blood viscosity, indicating

show abstract

1 Blood rheology in vitro and in vivo

Cited by 108 publications

References 99 publications

Whole blood viscosity and arterial thrombotic events in patients with systemic lupus erythematosus

Whole blood viscosity and arterial thrombotic events in patients with systemic lupus erythematosus

Cryoprecipitate transfusion: assessing appropriateness and dosing in trauma

Haemorheological effects of losartan and enalapril in patients with renal parenchymal disease and hypertension

Contact Info

Product

Resources

About